TA
REGN icon

TFB Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

TFB Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-899
Closed -$472K – 343
2025
Q2 		$472K Buy
899
+253
+39% +$141K 0.12% 189
2025
Q1 		$410K Buy
646
+7
+1% +$4.82K 0.12% 198
2024
Q4 		$455K Sell
639
-77
-11% -$64.6K 0.13% 177
2024
Q3 		$753K Buy
716
+30
+4% +$33.4K 0.22% 105
2024
Q2 		$721K Sell
686
-5
-0.7% -$4.85K 0.23% 96
2024
Q1 		$624K Buy
691
+318
+85% +$302K 0.23% 99
2023
Q4 		$328K Sell
373
-240
-39% -$198K 0.17% 117
2023
Q3 		$504K Buy
613
+63
+11% +$49.5K 0.61% 47
2023
Q2 		$395K Buy
550
+130
+31% +$100K 0.17% 139
2023
Q1 		$345K Buy
420
+57
+16% +$43K 0.26% 74
2022
Q4 		$262K Buy
+363
New +$268K 0.22% 98

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TFB Advisors's REGN Position: Q3 2025 in Review

TFB Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 899 shares — an estimated $472K sold.

TFB Advisors first reported a position in REGN in Q4 2022 and held it in 11 quarters. The position peaked at $753K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • TFB Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • TFB Advisors sold 899 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $472K.
  • TFB Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • TFB Advisors's Regeneron Pharmaceuticals position peaked at $753K in Q3 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on TFB Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.